Atea's hepatitis C combo therapy shows non-inferior results to Gilead's Epclusa

Atea Pharmaceuticals announced that its oral combination of bemnifosbuvir and ruzasvir met the predefined non-inferiority criteria when compared with Gilead's Epclusa for treating hepatitis C.

The head‑to‑head study demonstrated similar efficacy outcomes, suggesting the new regimen could serve as an alternative option for patients.

At the same time, antibody‑discovery firm AbCellera disclosed that it has entered into a second partnership agreement within the past two months, highlighting its ongoing collaboration strategy.

These developments may affect treatment choices and competitive dynamics in the hepatitis C market.